Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Sezary Syndrome 1Osteosarcoma 1Neuroblastoma 1Mycosis Fungoides 1Leukemia, Myeloid, Acute 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Brain Neoplasms 1

Interventions

Cyclophosphamide 13Specimen Handling 9cabozantinib 8X-Rays 8Magnetic Resonance Spectroscopy 8fludarabine 7Phantoms, Imaging 7Biopsy 7Temozolomide 6Methotrexate 6Zoledronic Acid 5Gemcitabine 5Doxorubicin 5regorafenib 4pembrolizumab 4Vincristine 4Nuclear Medicine Department, Hospital 4Nivolumab 4Ifosfamide 4Cisplatin 4olaparib 3irinotecan sucrosofate 3fludarabine phosphate 3dinutuximab 3Surveys and Questionnaires 3Irinotecan 3Etoposide 3ulixertinib 2tipifarnib 2tazemetostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × magrolimab × 1 year × Clear all
NCT04751383 2026-01-21

Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled 12 charts
CNSSarcoma

Neuroblastoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡